Details for Patent: 8,906,851
✉ Email this page to a colleague
Title: | Method for treating diabetes |
Abstract: | Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA.sub.1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided. |
Inventor(s): | Fineman; Mark (San Diego, CA), MacConell; Leigh (San Diego, CA), Taylor; Kristin (San Diego, CA) |
Assignee: | Amylin Pharmaceuticals, LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE) |
Filing Date: | Dec 07, 2012 |
Application Number: | 13/708,474 |
Claims: | 1. A method for treating diabetes in a human in need thereof comprising administering once weekly to the human a therapeutically effective amount of a pharmaceutical composition comprising exendin-4 to achieve a mean steady state plasma concentration of the exendin-4 of at least 170 pg/ml for at least one month in the human to treat diabetes, wherein the pharmaceutical composition further comprises a sugar. 2. The method of claim 1, wherein the exendin 4 is present in the pharmaceutical composition in an amount of 1.0 mg to 5.0 mg. 3. The method of claim 1, wherein the pharmaceutical composition comprises 5% (w/w) exendin-4, 2% (w/w) sucrose, and 93% (w/w) poly(lactide-co-glycolide)copolymer. 4. The method of claim 1, wherein the mean steady state plasma concentration of exendin 4 is 170 pg/ml to 600 pg/ml. 5. The method of claim 1, wherein the mean steady state plasma concentration of exendin 4 is 170 pg/ml to 350 pg/ml. 6. The method of claim 1, wherein the mean steady state plasma concentration of exendin 4 is 170 pg/ml to 290 pg/ml. 7. The method of claim 1, wherein the diabetes is type 2 diabetes. 8. The method of claim 1, wherein the diabetes is type 1 diabetes. |